Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 286, Issue 1 55-1, 2004, Pages

  Mizuno, Shinya ^a   Nakamura, Toshikazu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic renal failure; Glomerular sclerosis; Hepatocyte growth factor; Transforming growth factor

Indexed keywords

COLLAGEN; IMMUNOGLOBULIN G; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MODEL; FEMALE; FIBROGENESIS; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTROPHY; KIDNEY DYSFUNCTION; KIDNEY INJURY; MESANGIUM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; STREPTOZOCIN DIABETES;

EID: 0346099296     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00199.2003     Document Type: Article

References (48)

1. Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis 38: S195-S199, 2001.
2. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Wega A, Otsuki Y, Kitamura M, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, and Nakamura T. Hepatocyte growth factor prevents development of chronic allograft nephropathy in an experimental rat transplant model. J Am Soc Nephrol 12: 1280-1292, 2001.
3. Balkovetz DF and Lipschutz JH. Hepatocyte growth factor and the kidney: it is not just for the liver. Int Rev Cytol 186: 225-260, 1999.
4. Bessho K, Mizuno S, Matsumoto K, and Nakamura T. Counteractive effects of HGF on PDGF-mediated mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol Renal Physiol 284: F1171-F1180, 2003.
5. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, and Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 187: 251-259, 1991.
6. Border WA and Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
7. Brenner BM, Meyer TW, and Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307: 652-659, 1982
8. Chen N, Chen WY, Bellush L, Yang CW, Striker LJ, Striker JE, and Kopchick JJ. Effects of STZ treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 136: 660-667, 1995.
9. Eddy AA and Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47: 1546-1557, 1995.
10. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, and Nahas AM. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 12: 43-50, 1997.
11. Fornoni A, Li H, Foschi A, Striker GE, and Striker LJ. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin-A-induced apoptosis. Am J Pathol 158: 275-280, 2001.
12. Gilbert RE and Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56: 1627-1637, 1999.
13. Goldfar S and Ziyadeh FN. TGF-β: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 112: 27-32, 2001.
14. Igawa T, Matsumot K, Kanda S, Saito Y, and Nakamura T. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol Renal Fluid Electrolyte Physiol 265: F61-F69, 1993.
15. 1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6-nephrectomized mice. FASEB J 17: 268-270, 2003.
16. Kawaida K, Matsumoto K, Shimazu H, and Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 91: 4357-4361, 1994.
17. Kriz W and Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8: 489-497, 1999.
18. Laping NJ, Olson BA, Ho T, Ziyadeh FN, and Albrightson CR. Hepatocyte growth factor: a regulator of extracellular matrix genes in mouse mesangial cells. Biochem Pharmacol 59: 847-853, 2000.
19. Lazarus JM, Denker BM, and Owen WF. Hemodialysis. In: The Kidney (5th ed.), edited by Brenner BM. Philadelphia: W. B. Saunders, 1996, p. 2424-2506.
20. Liu Y, Raju K, Tolbert E, and Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2043, 2000.
21. Matsumoto K and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
22. 1 and glucocorticoids. J Biol Chem 267: 24917-24920, 1992.
23. Mizuno S, Kurosawa T, Matumoto K, Mizuno-Horikawa Y, Okamoto M, and Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101: 1827-1834, 1998.
24. 1 in renal fibrosis in mice. Kidney Int 57: 937-948, 2000.
25. Mizuno S, Matsumoto K, and Nakamura T. Hepatocyte growth factor suppresses tubulo-interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59: 1304-1314, 2001.
26. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. Potential role of an endothelium specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46: 138-142, 1997.
27. Nakamura T, Nawa K, and Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122: 1450-1459, 1984.
28. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
29. Ong AC and Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int 45: 345-351, 1994.
30. Ozaki I, Zhao G, Mizuta T, Ogawa Y, Hara T, Kajihara S, Hisatomi A, Sakai T, and Yamamoto K. HGF induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 36: 169-178, 2000.
31. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 335: 1682-1683, 1996.
32. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, and Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11: 25-38, 2000.
33. Sharma K, Jin Y, Guo J, and Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
34. Sharma K and Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146, 1995.
35. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sata W, Morita Y, Maruyama H, Egashira K, and Matsuo S. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injuries induced by protein-overload proteinuria. J Am Soc Nephrol 14: 1496-1505, 2003.
36. Singh R, Alavi N, Singh AK, and Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48: 2066-2073, 1999.
37. Takahashi T, Huynh-Do U, and Daniel TO. Renal microvascular assembly and repair: power and promise of molecular definition. Kidney Int 53: 826-835, 1998.
38. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim H, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102: 246-252, 2000.
39. Taylor GA, Jeffers M, Webb CP, Koo HM, Anve M, Sekiguchi K, and Vande-Woude GF. Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. Oncogene 17: 1179-1183, 1998.
40. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the developmental and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352: 837-853, 1998.
42. Wang SN, Lapage J, and Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 57: 1002-1014, 2000.
43. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
44. Yang J, Dai C, and Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther 8: 1470-1479, 2001.
45. Yang J and Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284: F349-F357, 2003.
46. Yang R, Bunting S, Ko A, Schwall R, and Jin H. Hemodynamic effects of scatter factor in concious rats. J Cardiovasc Pharmacol 30: 294-301, 1997.
47. Ziyadeh FN, Hoffman BB, Han CC, Iglesias-Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.
48. Ziyadeh FN, Sharma K, Ericksen M, and Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 93: 536-542, 1994.